Loncastuximab tesirine
ADCT-402-201
Phase 2 small_molecule completed
Quick answer
Loncastuximab tesirine for Diffuse Large B-Cell Lymphoma Refractory is a Phase 2 program (small_molecule) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ADC Therapeutics SA
- Indication
- Diffuse Large B-Cell Lymphoma Refractory
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed